Abstract
Background Recombinant vesicular stomatitis virus expressing interferon-β (VSV-IFN-β) has demonstrated antitumor activity in vitro and in vivo. In preparation for clinical testing in human squamous cell carcinoma (SCC) of the head and neck, we conducted preclinical studies of VSV-IFN-β in syngeneic SCC models. Methods In vitro, VSV-IFN-β (expressing rat or mouse interferon [IFN]-β)-induced cytotoxicity and propagated in rat (FAT-7) or mouse (SCC-VII) SCC cells during normoxia and hypoxia. In vivo, intratumoral administration of VSV-rat-IFN-β or VSV-human-IFN-β in FAT-7 bearing or non-tumor bearing immunocompetent rats did not result in acute organ toxicity or death. Results VSV-r-IFN-β replicated predominantly in tumors and a dose dependent anti-VSV antibody response was observed. Intratumoral or intravenous administration of VSV-IFN-β resulted in growth delay and improved survival compared with controls. Conclusion The above data confirm safety and feasibility of VSV-IFN-β administration in immunocompetent animals and support its clinical evaluation in advanced human head and neck cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 1619-1627 |
Number of pages | 9 |
Journal | Head and Neck |
Volume | 36 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2014 |
Keywords
- biodistribution
- preclinical studies
- squamous cell carcinoma
- syngeneic models
- vesicular stomatitis virus
ASJC Scopus subject areas
- Otorhinolaryngology